How selinexor (Xpovio) is positioned in competitive R/R DLBCL market?
Karyopharm’s Selinexor (Xpovio) an oral selective inhibitor of nuclear export (SINE) compound inhibiting the nuclear export protein exportin 1 (XPO1) was granted accelerated approval for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma. The drug is also approved a year ago as the “last line” treatment option for relapsed/refractory Multiple Myeloma patients.
Key Takeaways by Mellalta Meets
Selinexor (Xpovio) Marketing Positioning Statements
- First oral therapy approved for RR DLBCL
- First single agent approved in any line of DLBCL treatment
- First therapy a RR DLBCL patient can take at home
Selinexor (Xpovio) Market Positioning
- Selinexor (Xpovio) will be preferred as a DLBCL treatment option after two prior lines of therapy
- An Estimated 9,000 DLBCL Patients Being Treated in the 3rd and 4th Line+ Setting in the U.S.
- Recent FDA approvals of CAR-T therapy (2017 and 2019) and polatuzumab + bendamustine + rituximab (2019)
The approval of Karyopharm’s Xpovio (selinexor) in patients with relapsed or refractory DLBCL is a huge milestone for the patients and families suffering as they have limited treatment options available for their disease.
Click here for more information on the direct and Indirect competitors for Elacestrant in ER+/HER2- mBC. If you wish to learn more on how Mellalta can be of assistance, Click here.
